{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:15:53Z","timestamp":1768533353498,"version":"3.49.0"},"reference-count":133,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>Multiple myeloma (MM) is the leading indication of autologous hematopoietic stem cell transplantation (AHSCT) worldwide. The collection of PBSCs is the essential step for AHSCT. The limits for minimum and optimum CD34<jats:sup>+<\/jats:sup> cells collected have been accepted as 2 \u00d7 10<jats:sup>6<\/jats:sup>\/kg and \u22654 \u00d7 10<jats:sup>6<\/jats:sup>\/kg for single AHSCT; 4 \u00d7 10<jats:sup>6<\/jats:sup>\/kg and \u22658\u201010 \u00d7 10<jats:sup>6<\/jats:sup>\/kg for double AHSCT. Despite the success of conventional methods for PBSC mobilization in MM, mobilization failure is still a concern depending on patient age, duration of disease, and the type of induction therapy. By definition, \u201cproven poor mobilizer\u201d is the occurrence of mobilization failure (CD34+ cell peak &lt;20\/\u00b5L peripheral blood) after adequate preparation (after 6 days of G\u2010CSF 10 \u00b5g\/kg body weight alone or after 20 days of G\u2010CSF &gt;5 \u00b5g\/kg body weight following chemotherapy) or a CD34+ cell yield of &lt;2.0 \u00d7 10<jats:sup>6<\/jats:sup>\/kg body weight after three consecutive apheresis. \u201c<jats:italic>Predicted poor mobilizer<\/jats:italic>\u201d involves (1) a failure of a previous collection attempt OR (2) a previous history of extensive radiotherapy or full courses of therapy affecting mobilization OR (3) the presence of at least two of the following features: advanced disease (&gt;2 lines of chemotherapy), refractory disease, extensive bone marrow involvement or cellularity of 30% at the time of mobilization or age &gt;65 years. This article aims at discussing the risk factors for mobilization failure in the era of novel antimyeloma drugs, defining the poor mobilizer concept and summarizing the current and future strategies for the prevention and management of mobilization failures in MM.<\/jats:p>","DOI":"10.1002\/jca.21591","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T13:48:11Z","timestamp":1507211291000},"page":"357-370","source":"Crossref","is-referenced-by-count":8,"title":["Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-0068","authenticated-orcid":false,"given":"Ugur","family":"Sahin","sequence":"first","affiliation":[{"name":"Department of Hematology Ankara University Medical School Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2214-5927","authenticated-orcid":false,"given":"Taner","family":"Demirer","sequence":"additional","affiliation":[{"name":"Department of Hematology Ankara University Medical School Ankara Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0551"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.09.010"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0408"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.06.004"},{"issue":"6","key":"e_1_2_8_8_1","first-page":"915","article-title":"Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony\u2010stimulating factor\u2010mobilized peripheral blood stem cells in patients with acute myelogenous leukemia","volume":"15","author":"Demirer T","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151860"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.141"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2547"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.170"},{"issue":"1","key":"e_1_2_8_16_1","first-page":"29","article-title":"Autologous transplantation with peripheral blood stem cells collected after granulocyte colony\u2010stimulating factor in patients with acute myelogenous leukemia","volume":"18","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.07.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.410"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.11.005"},{"issue":"6","key":"e_1_2_8_20_1","first-page":"937","article-title":"Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma","volume":"17","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704704"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.012"},{"issue":"7","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood.V95.7.2234","article-title":"Engraftment, clinical, and molecular follow\u2010up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high\u2010dose chemotherapy","volume":"95","author":"Lemoli RM","year":"2000","journal-title":"Blood."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-205013"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.131"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1714"},{"issue":"3","key":"e_1_2_8_27_1","first-page":"83","article-title":"Factors predictive of rapid engraftment after peripheral blood stem cell infusions","volume":"15","author":"Bensinger W","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41081008.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2002.00406.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01405.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.12.031"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0812-9"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.306"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0522"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404661"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.141"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141614"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405035"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405100"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.02.011"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404801"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.008"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.118"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.63"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8164"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.236"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903480728"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903452826"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05540.x"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.82"},{"issue":"11","key":"e_1_2_8_56_1","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood.V112.11.3470.3470","article-title":"Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bortezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma (MM)","volume":"112","author":"Goldschmidt H","year":"2008","journal-title":"Blood."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07981.x"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25143"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.061"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/106161299320389"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1547"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2012.06.008"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.013"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh142"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1328"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140106"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.684"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.130"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701902"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.01.001"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06744.x"},{"issue":"4","key":"e_1_2_8_73_1","first-page":"491","article-title":"Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels","volume":"17","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"e_1_2_8_74_1","first-page":"341","article-title":"Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels","volume":"17","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199502030-00011"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704291"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701398"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01520.x"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.07.015"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2011.01.005"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20281"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703571"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.10.018"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04072.x"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03264.x"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.161"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00573.x"},{"issue":"1","key":"e_1_2_8_88_1","first-page":"105","article-title":"Phase II study of autologous filgrastim (G\u2010CSF)\u2010mobilized peripheral blood progenitor cells to restore hemopoiesis after high\u2010dose chemotherapy for lymphoid malignancies","volume":"14","author":"Sheridan WP","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11287"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0675-5"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2010.10.001"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13204"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174946"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02896.x"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705908"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.018"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.05.003"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2015.09.002"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12606"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.002"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12813"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.39"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701671"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.78"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.133"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.010"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.119"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.014"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/931071"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01573.x"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.93"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.128"},{"issue":"1","key":"e_1_2_8_113_1","first-page":"131","article-title":"High\u2010dose fractionated total\u2010body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells","volume":"18","author":"Brunvand MW","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi017"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602724"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704153"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl044"},{"issue":"5","key":"e_1_2_8_118_1","first-page":"769","article-title":"High\u2010dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer","volume":"17","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21477"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705940"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5936"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.1015"},{"issue":"6","key":"e_1_2_8_123_1","first-page":"907","article-title":"Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation","volume":"15","author":"Demirer T","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"e_1_2_8_124_1","first-page":"527","article-title":"Syngeneic marrow transplantation in patients with multiple myeloma","volume":"18","author":"Bensinger WI","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184721"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1107-2"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1302"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.3727\/096368914X681739"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2156-2"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358614"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.03.007"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1429"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.8"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-009-8109-6"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21591","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T23:33:37Z","timestamp":1694993617000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jca.21591"],"URL":"https:\/\/doi.org\/10.1002\/jca.21591","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}